New Zealand supplier a2 Milk expects a gradual recovery in China sales following supply-chain disruptions that limited infant formula availability earlier this year [1], [2].
The slow rebound threatens the company's short-term profitability. Because infant formula is a critical revenue driver in the Chinese market, prolonged supply issues can lead to lost market share and diminished margins.
The company said it expects the recovery period to span six months through December 2026 [1]. This timeline suggests that the operational hurdles faced earlier in the year will continue to weigh on financial performance for the remainder of the calendar year.
Supply-chain disruptions caused a significant shortfall of infant formula products within China [1], [2]. These issues specifically impacted product availability during the fourth quarter of 2026 [2]. While the company has indicated that the primary supply-chain issues are now resolved, the lag in restocking and consumer demand recovery persists.
Financial analysts said that the resulting soft earnings margins are a direct consequence of the availability gap. The company must now navigate the process of restoring its distribution network to previous levels while managing investor expectations for the final months of the year.
The situation highlights the vulnerability of New Zealand dairy exporters to logistical bottlenecks in East Asia. As a2 Milk works to stabilize its presence in China, the company remains focused on ensuring that product flow meets the demands of the infant formula market [1], [2].
“a2 Milk expects a gradual recovery in China sales following supply-chain disruptions”
The gradual recovery timeline indicates that resolving a physical supply shortage does not immediately translate to financial recovery. For a2 Milk, the 'soft margins' expected through the end of 2026 reflect the time required to rebuild inventory levels and regain consumer trust in product availability within a highly competitive Chinese regulatory environment.
